Sunday, November 21, 2021
1:30 PM – 2:30 PM CST
Please note this virtual program is 2:30PM Eastern, 1:30PM Central, 12:30PM Mountain and 11:30AM Pacific.
Please note, you must be registered to attend Annual Meeting for ASDS 2021 taking place November 19-21, 2021 in order to view the presentation. To register, please visit: https://www.asds.net/medical-professionals/annual-meeting/asds-annual-meeting-registration-start
- 3D Animations
- Interactive, case-based learning environment
- Complimentary Personalized Online Poster Portal
Emily Ruiz, MD, MPH
Associate Physician, Mohs and
Dermatologic Surgery Center
Director, Dana Farber High Risk Cancer Clinic
Assistant professor in Dermatology, Harvard Medical School
Director of the High-Risk Skin Cancer Clinic
Chrysalyne D. Schmults, MD, MSCE
Associate Professor of Dermatology, Harvard Medical School
Vice-Chair of Surgical Oncology, Brigham and Women’s Department of Dermatology
This activity is designed to meet the educational needs of Mohs surgeons, onco-dermatologists, medical oncologists, dermatologists and other healthcare practitioners who care for patients with advanced/metastatic basal cell skin cancer.
After completing the CME activity, learners should be better able to:
- Discuss the pathogenic drivers of BCC including cellular signaling pathways and immune dysfunction
- Review the utility of Mohs micrographic surgery in the evaluation and therapeutic intervention of BCC
- Describe systemic therapeutic approaches in the treatment of locally advanced and metastatic BCC
- Summarize the clinical trial data for emerging immunotherapy agents for advanced or metastatic basal cell skin cancer
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For questions, please contact: Med Learning Group at email@example.com.
Contact this provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org